-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the AI pharmacy track has been very hot
.
Looking at the world, large multinational pharmaceutical companies such as Novartis, Pfizer, GSK, AstraZeneca, and Sanofi have already tested the waters of AI research and development of new drugs, and have been attacking the city in the AI pharmaceutical track
.
It is worth mentioning that the current time has come to 2022.
In less than half a month, many large pharmaceutical companies have announced that they will make new moves in the field of AI
.
Under the AI pharma boom, pharmaceutical machine companies will accelerate their deployment in this track (Photo source: PharmaNet) Major pharmaceutical companies are accelerating the development of AI drugs Recently, Amgen announced that it has reached a research cooperation agreement with Generate Biomedicines
.
The two companies will leverage the artificial intelligence (AI) drug discovery technology platform developed by Generate to develop protein therapeutics against the top 5 clinical targets across multiple therapeutic areas and treatment modalities
.
Absci also announced a $610 million research collaboration with Merck
.
The two companies will leverage Absci's AI-driven drug innovation platform for drug development
.
In addition, Sanofi also announced a research collaboration license agreement of up to $5.
2 billion with Exscientia to jointly develop up to 15 products in the fields of oncology and immunology through the end-to-end AI-driven personalized medicine platform developed by Exscientia Novel small molecule drug candidates
.
It is worth noting that, in addition to multinational companies, domestic pharmaceutical companies are also actively deploying the AI pharmaceutical track
.
On January 11, Fosun Pharma and Insilicon announced a "marriage".
The two parties will jointly promote the research and development of AI drugs for multiple targets on a global scale
.
According to the agreement, Insilicon will receive an upfront payment of US$13 million and milestone payments, and share in the commercialization profits of the QPCTL project
.
In fact, in addition to Fosun Pharma, since 2021, many domestic pharmaceutical companies have been entering the AI pharmaceutical industry through strategic cooperation and equity investment
.
Analysis believes that behind the entry of pharmaceutical companies into the AI pharmacy track is actually a contest of R&D speed
.
Production efficiency has always been a difficult problem in the development of new drugs
.
Different from traditional pharmaceuticals, AI pharmaceuticals have the advantages of shortening the development cycle of new drugs, improving the success rate of new drug development, and reducing pharmaceutical costs.
It is no wonder that domestic and foreign pharmaceutical companies are so enthusiastic about AI
.
With the increasing recognition of AI pharmaceuticals in China, the industry predicts that the AI pharmaceutical industry will be extremely hot in the future, and the pharmaceutical industry will inevitably enter the era of AI pharmaceuticals
.
The rise of the AI pharmacy boom may have a great impact on pharmaceutical machine companies.
With the wider and wider application of AI, the pharmaceutical industry has entered the era of AI pharmacy.
Some people in the industry have proposed that in addition to the pharmaceutical field, the integration of AI and the pharmaceutical equipment industry will also further Acceleration will play an important role in equipment innovation and management in the future
.
In fact, many pharmaceutical equipment companies have already begun to join the exploration of AI + pharmaceutical equipment, and have carried out active practices
.
For example, many companies are concentrating on promoting the production model of "robots instead of manual labor", using Internet technology, Internet of Things technology, automated logistics systems and other technologies to break the traditional process
.
In general, AI is gradually becoming a new breakthrough in promoting the high-quality development of the pharmaceutical equipment industry, which continues to have an impact on technological innovation, management, and systems
.
In the future, with the continuous improvement of AI technology, the industry predicts that the technological transformation and optimization and upgrading of the pharmaceutical equipment industry will continue, and the future pharmaceutical equipment industry model and enterprise form may usher in fundamental changes
.
.
Looking at the world, large multinational pharmaceutical companies such as Novartis, Pfizer, GSK, AstraZeneca, and Sanofi have already tested the waters of AI research and development of new drugs, and have been attacking the city in the AI pharmaceutical track
.
It is worth mentioning that the current time has come to 2022.
In less than half a month, many large pharmaceutical companies have announced that they will make new moves in the field of AI
.
Under the AI pharma boom, pharmaceutical machine companies will accelerate their deployment in this track (Photo source: PharmaNet) Major pharmaceutical companies are accelerating the development of AI drugs Recently, Amgen announced that it has reached a research cooperation agreement with Generate Biomedicines
.
The two companies will leverage the artificial intelligence (AI) drug discovery technology platform developed by Generate to develop protein therapeutics against the top 5 clinical targets across multiple therapeutic areas and treatment modalities
.
Absci also announced a $610 million research collaboration with Merck
.
The two companies will leverage Absci's AI-driven drug innovation platform for drug development
.
In addition, Sanofi also announced a research collaboration license agreement of up to $5.
2 billion with Exscientia to jointly develop up to 15 products in the fields of oncology and immunology through the end-to-end AI-driven personalized medicine platform developed by Exscientia Novel small molecule drug candidates
.
It is worth noting that, in addition to multinational companies, domestic pharmaceutical companies are also actively deploying the AI pharmaceutical track
.
On January 11, Fosun Pharma and Insilicon announced a "marriage".
The two parties will jointly promote the research and development of AI drugs for multiple targets on a global scale
.
According to the agreement, Insilicon will receive an upfront payment of US$13 million and milestone payments, and share in the commercialization profits of the QPCTL project
.
In fact, in addition to Fosun Pharma, since 2021, many domestic pharmaceutical companies have been entering the AI pharmaceutical industry through strategic cooperation and equity investment
.
Analysis believes that behind the entry of pharmaceutical companies into the AI pharmacy track is actually a contest of R&D speed
.
Production efficiency has always been a difficult problem in the development of new drugs
.
Different from traditional pharmaceuticals, AI pharmaceuticals have the advantages of shortening the development cycle of new drugs, improving the success rate of new drug development, and reducing pharmaceutical costs.
It is no wonder that domestic and foreign pharmaceutical companies are so enthusiastic about AI
.
With the increasing recognition of AI pharmaceuticals in China, the industry predicts that the AI pharmaceutical industry will be extremely hot in the future, and the pharmaceutical industry will inevitably enter the era of AI pharmaceuticals
.
The rise of the AI pharmacy boom may have a great impact on pharmaceutical machine companies.
With the wider and wider application of AI, the pharmaceutical industry has entered the era of AI pharmacy.
Some people in the industry have proposed that in addition to the pharmaceutical field, the integration of AI and the pharmaceutical equipment industry will also further Acceleration will play an important role in equipment innovation and management in the future
.
In fact, many pharmaceutical equipment companies have already begun to join the exploration of AI + pharmaceutical equipment, and have carried out active practices
.
For example, many companies are concentrating on promoting the production model of "robots instead of manual labor", using Internet technology, Internet of Things technology, automated logistics systems and other technologies to break the traditional process
.
In general, AI is gradually becoming a new breakthrough in promoting the high-quality development of the pharmaceutical equipment industry, which continues to have an impact on technological innovation, management, and systems
.
In the future, with the continuous improvement of AI technology, the industry predicts that the technological transformation and optimization and upgrading of the pharmaceutical equipment industry will continue, and the future pharmaceutical equipment industry model and enterprise form may usher in fundamental changes
.
